- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03185364
The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD
June 11, 2017 updated by: Jianguo He, Chinese Academy of Medical Sciences, Fuwai Hospital
Over half of chronic obstructive pulmonary disease (COPD) patients develop pulmonary hypertension.
The current therapy focuses only on the basic disease and there are a lot of controversies about the use of PAH target therapy in group 3 pulmonary hypertension.
Our study is to explore whether sildenafil, a pulmonary arterial hypertension (PAH) target drug, could be efficient and safe in improving symptoms and survival of severe pulmonary hypertension caused by COPD.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology
-
Contact:
- Guohua Hu, MD
- Phone Number: 13517277794
- Email: guohuazhen@hotmail.com
-
Contact:
- Phone Number: 13517277794
- Email: guohuazhen@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Stable for over 1 month
- mean pulmonary artery pressure ≥35mmHg, pulmonary wedge pressure≤ 15mmHg
- never received target therapy before
Exclusion Criteria:
- Patients with other serious respiratory diseases
- Patients with pulmonary hypertension other than group 3
- Patients with right heart hypertrophy or dysfunction not caused by chronic obstructive pulmonary diseases
- Patients with limited life expectancy
- Patients with history of tracheal intubation or stoke, acute coronary syndrome in 6 months
- Psychopath or addict
- Nonstable patients with type Ⅰor Ⅱ respiratory failure
- Patients with contraindication for sildenafil
- Patients in pregnancy or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional group
Sildenafil Citrate, 20mg, tid for 12 weeks
|
sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
|
Placebo Comparator: Control group
placebo oral tablet, 12 weeks
|
placebos treatment for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pulmonary artery pressure
Time Frame: 12 weeks
|
pressure in mmHg
|
12 weeks
|
pulmonary vascular resistance
Time Frame: 12 weeks
|
woods
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 15, 2017
Primary Completion (Anticipated)
December 31, 2020
Study Completion (Anticipated)
December 31, 2020
Study Registration Dates
First Submitted
June 11, 2017
First Submitted That Met QC Criteria
June 11, 2017
First Posted (Actual)
June 14, 2017
Study Record Updates
Last Update Posted (Actual)
June 14, 2017
Last Update Submitted That Met QC Criteria
June 11, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension
- Hypertension, Pulmonary
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
- 2016YFC1304401B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
BayerCompletedPrimary HypertensionChina
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
Clinical Trials on Sildenafil Citrate
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
University of PennsylvaniaWalter Reed National Military Medical CenterRecruiting
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
University of Mississippi Medical CenterActive, not recruiting
-
Pfizer's Upjohn has merged with Mylan to form Viatris...No longer availablePulmonary Arterial HypertensionIndia
-
Federal University of São PauloUniversity of Sao PauloCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedScleroderma, Systemic | Scleroderma, Diffuse | Raynaud Phenomenon | Scleroderma, LimitedBrazil